99
Participants
Start Date
November 1, 2006
Primary Completion Date
April 1, 2010
Study Completion Date
December 1, 2010
Amrubicin
"Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression."
Cisplatin
"Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression."
Etoposide
Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Algemeen Ziekenhuis Middelheim, Antwerp
Universitair Ziekenhuis Antwerpen, Edegem
U.Z. Gasthuisberg, Leuven
Centre Hospitalier Regional de la Citadelle, Liège
Clinique Sainte Elisabeth, Namur
Academisch Ziekenhuis Maastricht, Maastricht
Isala Kliniek, Zwolle
Universiteit Gent, Ghent
Instituto Nazionale per la Ricerca sul Cancro, Genova
Universita Degli Studi Di Udine, Udine
Medical University of Gdansk - Dept Radiotherapy, Gdansk
Domaine Universitaire du Sart-Tilman, Liège
Academisch Medisch Centrum, Amsterdam
The Netherlands Cancer Institute Antoni Van Leeuwenhoekziekenhuis, Amsterdam
Medisch Spectrum Twente - Dept of Pulmonary Diseases, Enschede
Leiden University Medical Centre, Leiden
Clatterbridge Centre for Oncology NHS Trust, Bebington
University of Dundee - Ninewells Hospital, Dundee
Belfast City Hospital, Belfast
Western General Hospital, Edinburgh
Princess Royal Hospital, Hull
Royal Marsden Hospital, London, London
Christie Hospital, Manchester
Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne
Royal Marsden Hospital Lung Unit, Sutton
Lead Sponsor
Celgene
INDUSTRY